Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biostar Stem Cell Research Institute
Seoul, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
Biostar has received approval in Japan for its autologous fat-derived mesenchymal stem cell therapy for ASD and Parkinson's disease. Clinical results are assessed by the Social Responsiveness Scale-2 for ASD and ongoing evaluation for Parkinson’s. No US FDA approval for orphan indications, but designated for Buerger’s disease
- Therapeutic areas
- CardiovascularNeurologyEndocrinologyPsychiatry
- Modalities
- Stem cell therapyMesenchymal stem cell therapyAutologous adipose tissue-derived stem cell therapy
- Industry
- Biotech
02
Partnerships
RBio (Korea)Nature CellJapan Angel Stem Cell (JASC)Osaka Trinity Clinic (Japan)Kudo Clinic (Tokyo, for Parkinson’s)
Beyond the preview
Go deeper on Biostar Stem Cell Research Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biostar Stem Cell Research Institute.